Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round

John Carroll

Bio has jumped out of stealth mode–more or less–with a $ 51 million A and plans to combine two platform technologies into a next-gen approach on immunotherapies. The company was founded in 2014 and quietly launched a few months ago, says ex-Kite CEO and Adicet founder Aya Jakobovitz, who's been working as a partner at while she assembled her new team.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS